The JI PBL Intereron Source
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jahn-Schmid, B.
Right arrow Articles by Ebner, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jahn-Schmid, B.
Right arrow Articles by Ebner, C.
Right arrowPubmed/NCBI databases
*Substance via MeSH
The Journal of Immunology, 2002, 169: 6005-6011.
Copyright © 2002 by The American Association of Immunologists

The T Cell Response to Art v 1, the Major Mugwort Pollen Allergen, Is Dominated by One Epitope1

Beatrice Jahn-Schmid*, Peter Kelemen*, Martin Himly{dagger}, Barbara Bohle*, Gottfried Fischer{ddagger}, Fatima Ferreira{dagger} and Christof Ebner2,*

* Department of Pathophysiology, Division of Immunopathology, University of Vienna, Vienna, Austria; {dagger} Institute of Genetics, University of Salzburg, Salzburg, Austria; and {ddagger} Department of Blood Group Serology, University of Vienna, Vienna, Austria

Mugwort (Artemisia vulgaris) pollen allergens represent the main cause of pollinosis in late summer in Europe. At least 95% of sera from mugwort pollen-allergic patients contain IgE against a highly glycosylated 24- to 28-kDa glycoprotein. Recently, this major allergen, termed Art v 1, was characterized, cloned in Escherichia coli, and produced in recombinant form. In the present study we characterized and compared the T cell responses to natural (nArt v 1) and recombinant Art v 1 (rArt v 1). In vitro T cell responses to nArt v 1 and rArt v 1 were studied in PBMC, T cell lines (TCL), and T cell clones (TCC) established from PBMC of mugwort-allergic patients. Stimulation of PBMC or allergen-specific TCL with either nArt v 1 or rArt v 1 resulted in comparable proliferative T cell responses. Eighty-five percent of the TCC reactive with rArt v 1 cross-reacted with the natural protein. The majority of the CD4+CD8-TCR {alpha}{beta}+ Art v 1-specific TCC, obtained from 10 different donors, belonged to the Th2 phenotype. Epitope mapping of TCL and TCC using overlapping peptides revealed a single immunodominant T cell epitope recognized by 81% of the patients. Inhibition experiments demonstrated that the presentation of this peptide is restricted by HLA-DR molecules. In conclusion, the T cell response to Art v 1 is characterized by one strong immunodominant epitope and evidently differs from the T cell responses to other common pollen allergens known to contain multiple T cell epitopes. Therefore, mugwort allergy may be an ideal candidate for a peptide-based immunotherapy approach.




This article has been cited by other articles:


Home page
J. Immunol.Home page
B. Jahn-Schmid, P. Sirven, V. Leb, W. F. Pickl, G. F. Fischer, G. Gadermaier, M. Egger, C. Ebner, F. Ferreira, B. Maillere, et al.
Characterization of HLA Class II/Peptide-TCR Interactions of the Immunodominant T Cell Epitope in Art v 1, the Major Mugwort Pollen Allergen
J. Immunol., September 1, 2008; 181(5): 3636 - 3642.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
B. Janjic, P. Andrade, X.-F. Wang, J. Fourcade, C. Almunia, P. Kudela, A. Brufsky, S. Jacobs, D. Friedland, R. Stoller, et al.
Spontaneous CD4+ T Cell Responses against TRAG-3 in Patients with Melanoma and Breast Cancers
J. Immunol., August 15, 2006; 177(4): 2717 - 2727.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 2002 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 2002 by The American Association of Immunologists, Inc. All rights reserved.